You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020367038
Dec 20204408
Jan 202172011
Feb 202172012
Mar 202184017
Apr 20214008
May 20212504
Jun 2021009
Jul 20210015
Aug 20210018
Sep 20210025
Oct 202172030
Nov 2021150034
Dec 202158013
Jan 202284014
Feb 20223804
Mar 20224809
Apr 20226409
May 202264016
Jun 2022108018
Jul 202292017
Aug 20223407
Sep 202270018
Oct 20225206
Nov 20225808
Dec 20222002
Jan 20234407
Feb 20234005
Mar 20234405
Apr 20233806
May 20231206
Jun 20231802
Jul 20232606
Aug 20232407
Sep 20233200
Oct 20235009
Nov 20233604
Dec 20237203
Jan 20242802
Feb 20243804
Mar 202456021
Apr 20242409
May 202444011
Jun 20243504
Jul 20243204
Aug 20243109
Sep 20244606
Oct 202464012
Nov 20242403
Dec 202470014
Jan 20252008
Feb 2025604
Mar 2025001
Apr 20250010
May 2025007
Jun 2025008
Total26700567